A once-a-day tablet for the treatment of adults with relapsing forms of multiple sclerosis (MS) was approved by the FDA. In a clinical trial, Aubagio (teriflunomide) has lowered the relapse rate for MS patients was about 30% lower than for placebo. For most patients with MS, episodes of worsening function (relapses) are initially followed by recovery periods (remissions) that progressively decline over time. Aubagio carries black box warnings concerning the risk of liver problems and birth defects and is labeled as Pregnancy Category X. The drug, which is manufactured by Sanofi-Aventis of Bridgewater, New Jersey, will be dispensed with a patient Medication Guide.